Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab top-down therapy versus azathioprine standard of care in newly diagnosed moderate-to-severe Crohn's disease
2026-525191-26-00Phase 4Authorised
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in Crohn's disease comparing Top-down mirikizumab with Standard of care azathioprine (2 arms). Primary endpoint: Deep remission at Week 52. Planned start Aug 2026; status: authorised.
02
Drugs
mirikizumabazathioprine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2026-525191-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525191-26-00.